Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer." /> Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer. Clin Cancer Res. 2026 Jan 5. doi: 10.1158/1078-0432.CCR-25-3080. " />

Read + Share

Keyl J, Hosch R, Horst F, Keyl P, et al. Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer. Clin Cancer Res 2026 Jan 5. doi: 10.1158/1078-0432.CCR-25-3080.
PMID: 41489691

• Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer.&body=Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer. Keyl J, Hosch R, Horst F, Keyl P, et al. Clin Cancer Res 2026 Jan 5. doi: 10.1158/1078-0432.CCR-25-3080. https://m.amedeo.com/41489691 " ALT="Email" TITLE="Email">Email

• Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer.&summary=Keyl J, Hosch R, Horst F, Keyl P, et al. Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer. Clin Cancer Res 2026 Jan 5. doi: 10.1158/1078-0432.CCR-25-3080.&source=https://m.amedeo.com" target="linkedin">LinkedIn

---

Privacy Policy